AIM: Limited data are available regarding pharmacological characteristics of effective interventions for psychosis prevention. Enrollment challenges in psychosis prevention trials impede screening diverse interventions for efficacy. Relevant animal models could help circumvent this barrier. We previously described prevention with risperidone of abnormal behavior following neonatal hippocampal lesion. We aimed to extend those findings evaluating risperidone and paliperidone following prenatal immune activation, a developmental model of a schizophrenia risk factor. We evaluated a later developmental time point to determine persistent effects of drug treatment. METHODS: Pregnant Sprague-Dawley rats were injected with poly I:C or saline on gestational day 14. Offspring of poly I:C and saline-treated dams received risperidone (0.45 mg/kg/d), paliperidone (0.05 mg/kg/d), or vehicle from postnatal days 35-70. Locomotor responses to novelty, saline injection, and amphetamine (1 and 5 mg/kg) were determined at three months, i.e., 21 days following antipsychotic discontinuation. RESULTS: Risperidone and paliperidone had persistent effects on behavioral response to amphetamine (1 mg/kg) at 3 months, ameliorating the impact of prenatal immune activation on offspring of poly I:C-treated dams. Risperidone, but not paliperidone, also exerted persistent effects in offspring of saline-treated dams on locomotor response to saline and amphetamine (5 mg/kg) injection. CONCLUSIONS: Risperidone and paliperidone pre-treatment of poly I:C offspring during peri-pubertal development stabilized response to amphetamine exposure persisting into early adulthood. Prenatal immune activation provides a model for evaluating effects of an environmental risk factor for schizophrenia, and has potential utility for identifying pharmacological approaches to early intervention. Published by Elsevier Ltd.
AIM: Limited data are available regarding pharmacological characteristics of effective interventions for psychosis prevention. Enrollment challenges in psychosis prevention trials impede screening diverse interventions for efficacy. Relevant animal models could help circumvent this barrier. We previously described prevention with risperidone of abnormal behavior following neonatal hippocampal lesion. We aimed to extend those findings evaluating risperidone and paliperidone following prenatal immune activation, a developmental model of a schizophrenia risk factor. We evaluated a later developmental time point to determine persistent effects of drug treatment. METHODS: Pregnant Sprague-Dawley rats were injected with poly I:C or saline on gestational day 14. Offspring of poly I:C and saline-treated dams received risperidone (0.45 mg/kg/d), paliperidone (0.05 mg/kg/d), or vehicle from postnatal days 35-70. Locomotor responses to novelty, saline injection, and amphetamine (1 and 5 mg/kg) were determined at three months, i.e., 21 days following antipsychotic discontinuation. RESULTS:Risperidone and paliperidone had persistent effects on behavioral response to amphetamine (1 mg/kg) at 3 months, ameliorating the impact of prenatal immune activation on offspring of poly I:C-treated dams. Risperidone, but not paliperidone, also exerted persistent effects in offspring of saline-treated dams on locomotor response to saline and amphetamine (5 mg/kg) injection. CONCLUSIONS:Risperidone and paliperidone pre-treatment of poly I:C offspring during peri-pubertal development stabilized response to amphetamine exposure persisting into early adulthood. Prenatal immune activation provides a model for evaluating effects of an environmental risk factor for schizophrenia, and has potential utility for identifying pharmacological approaches to early intervention. Published by Elsevier Ltd.
Authors: Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall Journal: Br J Psychiatry Date: 2004-10 Impact factor: 9.319
Authors: Alan S Brown; Melissa D Begg; Stefan Gravenstein; Catherine A Schaefer; Richard J Wyatt; Michaeline Bresnahan; Vicki P Babulas; Ezra S Susser Journal: Arch Gen Psychiatry Date: 2004-08
Authors: Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams Journal: Synapse Date: 2012-05-15 Impact factor: 2.562
Authors: Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger Journal: Nat Rev Drug Discov Date: 2016-03-04 Impact factor: 84.694
Authors: Neil M Richtand; Rebecca Ahlbrand; Paul Horn; Rabindra Tambyraja; Molly Grainger; Stefanie L Bronson; Robert K McNamara Journal: Physiol Behav Date: 2012-02-09
Authors: Neil M Richtand; Rebecca Ahlbrand; Paul S Horn; Brad Chambers; Jon Davis; Stephen Benoit Journal: Psychopharmacology (Berl) Date: 2012-07 Impact factor: 4.530
Authors: Karina S MacDowell; Javier R Caso; David Martín-Hernández; Beatriz M Moreno; José L M Madrigal; Juan A Micó; Juan C Leza; Borja García-Bueno Journal: Neurotherapeutics Date: 2016-10 Impact factor: 7.620
Authors: Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams Journal: Neurotoxicol Teratol Date: 2014-11-08 Impact factor: 3.763
Authors: Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost Journal: Int J Neuropsychopharmacol Date: 2013-01-25 Impact factor: 5.176